Home » Stocks » KTRA

Kintara Therapeutics, Inc. (KTRA)

Stock Price: $1.50 USD 0.00 (0.00%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $1.45 -0.05 (-3.33%) Jan 15, 7:52 PM
Market Cap 36.99M
Revenue (ttm) n/a
Net Income (ttm) -30.23M
Shares Out 17.11M
EPS (ttm) -2.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $1.50
Previous Close $1.50
Change ($) 0.00
Change (%) 0.00%
Day's Open 1.38
Day's Range 1.34 - 1.59
Day's Volume 1,133,849
52-Week Range 0.38 - 1.72

News

Hide News
PRNewsWire - 2 months ago

SAN DIEGO, Nov. 13, 2020 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cance...

PRNewsWire - 4 months ago

SAN DIEGO, Aug. 21, 2020 /PRNewswire/ -- Kintara Therapeutics, Inc. (formerly DelMar Pharmaceuticals, Inc.) ("Kintara" or the "Company") (Nasdaq: KTRA) announced today that it has entered into...

PRNewsWire - 4 months ago

SAN DIEGO, Aug. 21, 2020 /PRNewswire/ -- Kintara Therapeutics, Inc. (formerly DelMar Pharmaceuticals, Inc.) ("Kintara" or the "Company") (Nasdaq: KTRA) announced today that it has regained co...

About KTRA

Kintara Therapeutics, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast ... [Read more...]

Industry
Biotechnology
Founded
2009
CEO
Saiid Zarrabian
Employees
4
Stock Exchange
NASDAQ
Ticker Symbol
KTRA
Full Company Profile

Financial Performance

Financial Statements